Phase I study of a DNA-based vaccine targeting prostatic acid phosphatase (PAP) in patients with stage D0 prostate cancer.
Latest Information Update: 06 Sep 2024
At a glance
- Drugs MVI 816 (Primary) ; Granulocyte macrophage colony stimulating factor
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Pharmacodynamics
- 27 Sep 2010 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
- 19 Apr 2009 Status changed from active, no longer recruiting to completed, as reported in bstract number 729 presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR), held in Denver, Colorado, USA in April 2009.
- 18 Apr 2009 Primary outcome amended as reported by ClinicalTrials.gov.